5309-14-8

Basic information

• Product Name: 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE
• Synonyms: 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE;1-(4-Methoxyphenyl)-4-oxocyclohexanecarbonitrile
• CAS NO: 5309-14-8
• Molecular Formula: C₁₄H₁₅NO₂
• Molecular Weight: 229.277
• Mol File: 5309-14-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 369.3°C at 760 mmHg
• Flash Point: 177.2°C
• Appearance: /
• Density: 1.49g/cm³
• Vapor Pressure: 1.19E-05mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE(5309-14-8)
• EPA Substance Registry System: 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE(5309-14-8)

Safety Data

• Hazardous Substances Data: 5309-14-8(Hazardous Substances Data)

Usage

General Description

4-Cyano-4-(4-methoxyphenyl)cyclohexanone is a chemical compound with the molecular formula C15H17NO2. It is a member of the cyclohexanone family and contains a cyano group and a methoxyphenyl group. 4-CYANO-4-(4-METHOXYPHENYL)CYCLOHEXANONE is commonly used in organic synthesis and pharmaceutical research as a starting material for the synthesis of various compounds. It is also known for its potential pharmacological uses, including as an anti-inflammatory agent and as a potential target for drug discovery. Additionally, it has been studied for its potential applications in the field of medicinal chemistry for the development of new drugs.

InChI:InChI=1/C9H7Cl3N4/c1-4(2)15-16-9-7(11)6(10)5(3-13)8(12)14-9/h1-2H3,(H,14,16)

Upstream product

• 56326-96-6 methyl 5-cyano-5-(4-methoxyphenyl)-2-oxocyclohexanecarboxylate 

Relevant articles and documents

SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS

The invention relates to substituted isoquinoline and isoquinolinones of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

4-Arylcyclohexylamines

The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula SPC1 Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, EQU1 WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R1 and R2 taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.